The GLP is committed to full transparency. Download and review our Annual Report.

US patent office reopens Broad Institute—University of California CRISPR patent dispute

| | June 27, 2019

The U.S. patent office has declared an interference between a dozen key patents awarded to the Broad Institute on the genome-editing technology CRISPR and 10 CRISPR patent applications submitted by the University of California and its partners, according to documents posted by the U.S. Patent and Trademark Office.

The declaration of an interference means that the patent office has determined that one or more patent applications describe inventions that are substantially the same as those for which patents have already been issued. In this case, the patents awarded to the Broad, beginning in 2014, describe the use of CRISPR-Cas9 to edit the genomes of eukaryotes — organisms whose genomes are enclosed within a cell nucleus, including all plants and animals — based on the research of Broad biologist Feng Zhang. UC’s patent applications also cover the use of CRISPR in eukaryotes, based on the work of UC Berkeley biochemist Jennifer Doudna and her collaborator Emmanuelle Charpentier.

At some point, the patent office will therefore have to determine who was the inventor of CRISPR genome editing in higher organisms — not bacteria, and not DNA floating freely in a test tube.

Related article:  Drugs for mental disorders: Why better access to services ‘will likely make things worse’

Read full, original post: Patent office reopens major CRISPR battle between Broad Institute and Univ. of California

The GLP aggregated and excerpted this article to reflect the diversity of news, opinion, and analysis. Click the link above to read the full, original article.
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend